Assertio Holdings rises after $166 million buyout by Zydus
Shares of drugmaker Assertio Holdings ASRT.O rise 3.7% to $23.38 premarket
ASRT says Indian drugmaker Zydus Lifesciences ZYDU.NS will acquire the company for $23.50 per share or $166.4 million
The offer from Zydus Lifesciences' subsidiary Zydus Worldwide DMCC, tops Assertio's earlier merger agreement with Garda Therapeutics, ASRT says
Through the deal, Zydus will gain 8 FDA approved drugs for various conditions
Zydus' offer represents a 4% premium to ASRT's last close
The offer represents a 30.6% premium to Garda's original $18-per-share cash offer announced in April, and a 7.8% premium to Garda's revised $21.80-per-share offer announced on May 4, Assertio said
Assertio says the deal is expected to close in the second quarter of 2026
As of last close, ASRT was up 148% YTD
Recommended Articles













Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.